{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:11:54Z","timestamp":1780920714288,"version":"3.54.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92269204"],"award-info":[{"award-number":["92269204"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82421005"],"award-info":[{"award-number":["82421005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101120","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T17:15:27Z","timestamp":1769793327000},"page":"101120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Securinine bolsters anti-tumor immunity by promoting CD8\u207a T cell activation"],"prefix":"10.1016","volume":"47","author":[{"given":"Liangchen","family":"Gui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haowei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinlan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8670-517X","authenticated-orcid":false,"given":"Jin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101120_bib0001","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0006-8993(85)90014-9","article-title":"Securinine alkaloids: a new class of GABA receptor antagonist","volume":"330","author":"Beutler","year":"1985","journal-title":"Brain Res."},{"key":"10.1016\/j.ctarc.2026.101120_bib0002","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021203","article-title":"Securinine, a myeloid differentiation agent with therapeutic potential for AML","volume":"6","author":"Gupta","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ctarc.2026.101120_bib0003","doi-asserted-by":"crossref","first-page":"19185","DOI":"10.1039\/D1RA02558A","article-title":"Unique indolizidine alkaloid securinine is a promising scaffold for the development of neuroprotective and antitumor drugs","volume":"11","author":"Klochkov","year":"2021","journal-title":"RSC Adv."},{"key":"10.1016\/j.ctarc.2026.101120_bib0004","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.1974.03230280016013","article-title":"Letter: securinine","volume":"228","author":"Copperman","year":"1974","journal-title":"JAMA"},{"key":"10.1016\/j.ctarc.2026.101120_bib0005","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0378-8741(90)90069-6","article-title":"Antibacterial activity of the leaves of Phyllanthus discoideus","volume":"28","author":"Mensah","year":"1990","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ctarc.2026.101120_bib0006","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/8302636","article-title":"Anti-inflammatory and neuroprotective role of natural product securinine in activated glial cells: implications for Parkinson's Disease","volume":"2017","author":"Leonoudakis","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.ctarc.2026.101120_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154417","article-title":"Potential anticancer activities of securinine and its molecular targets","volume":"106","author":"Liu","year":"2022","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ctarc.2026.101120_bib0008","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.70036","article-title":"l-securinine induces ROS-dependent apoptosis on pancreatic cancer cells via the PI3K\/AKT\/mTOR signaling pathway","volume":"38","author":"Anastasiou","year":"2024","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.ctarc.2026.101120_bib0009","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1096\/fj.09-148999","article-title":"Securinine induces p73-dependent apoptosis preferentially in p53-deficient colon cancer cells","volume":"24","author":"Rana","year":"2010","journal-title":"FASEB J."},{"key":"10.1016\/j.ctarc.2026.101120_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114190","article-title":"Bioactivities and mechanism of action of securinega alkaloids derivatives reported prior to 2022","volume":"158","author":"Hou","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ctarc.2026.101120_bib0011","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.3892\/or.2014.3101","article-title":"l-securinine induces apoptosis in the human promyelocytic leukemia cell line HL-60 and influences the expression of genes involved in the PI3K\/AKT\/mTOR signaling pathway","volume":"31","author":"Han","year":"2014","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ctarc.2026.101120_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116125","article-title":"Securinine inhibits the tumor growth of human bladder cancer cells by suppressing wnt\/\u03b2-catenin signaling pathway and activating p38 and JNK signaling pathways","volume":"223","author":"Xie","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ctarc.2026.101120_bib0013","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1189\/jlb.0407255","article-title":"Securinine, a GABAA receptor antagonist, enhances macrophage clearance of phase II C. burnetii: comparison with TLR agonists","volume":"82","author":"Lubick","year":"2007","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.ctarc.2026.101120_bib0014","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.semcancer.2021.11.006","article-title":"Anticancer natural products targeting immune checkpoint protein network","volume":"86","author":"Chun","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ctarc.2026.101120_bib0015","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.semcancer.2019.06.011","article-title":"Unraveling the molecular mechanisms and the potential chemopreventive\/therapeutic properties of natural compounds in melanoma","volume":"59","author":"Fontana","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ctarc.2026.101120_bib0016","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.semcancer.2022.06.009","article-title":"Natural products and their derivatives as immune check point inhibitors: targeting cytokine\/chemokine signalling in cancer","volume":"86","author":"Gupta","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ctarc.2026.101120_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.110170","article-title":"Colon cancer and colorectal cancer: prevention and treatment by potential natural products","volume":"368","author":"Islam","year":"2022","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ctarc.2026.101120_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.111017","article-title":"Myricetin: a review of the most recent research","volume":"134","author":"Song","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ctarc.2026.101120_bib0019","doi-asserted-by":"crossref","first-page":"eabj3510","DOI":"10.1126\/science.abj3510","article-title":"Spermidine activates mitochondrial trifunctional protein and improves antitumor immunity in mice","volume":"378","author":"Al-Habsi","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.ctarc.2026.101120_bib0020","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/s41586-023-06749-3","article-title":"Trans-vaccenic acid reprograms CD8(+) T cells and anti-tumour immunity","volume":"623","author":"Fan","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ctarc.2026.101120_bib0021","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2022110636","article-title":"Disulfiram bolsters T-cell anti-tumor immunity through direct activation of LCK-mediated TCR signaling","volume":"41","author":"Wang","year":"2022","journal-title":"EMBO J."},{"key":"10.1016\/j.ctarc.2026.101120_bib0022","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.ctarc.2026.101120_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155608","article-title":"Targeting CD8(+) T cells with natural products for tumor therapy: revealing insights into the mechanisms","volume":"129","author":"Wang","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ctarc.2026.101120_bib0024","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/j.apsb.2020.06.014","article-title":"Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5","volume":"10","author":"Liu","year":"2020","journal-title":"Acta Pharm. Sin. B"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:49:29Z","timestamp":1780919369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226000316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":24,"alternative-id":["S2468294226000316"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101120","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Securinine bolsters anti-tumor immunity by promoting CD8\u207a T cell activation","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101120","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101120"}}